Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation technique for brain tumors under the microscope

NCT ID NCT05270707

Knowledge-focused Sponsor: Varian, a Siemens Healthineers Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study gathered information from nearly 1,000 patients who received or were scheduled to receive HyperArc stereotactic radiosurgery, a precise radiation treatment for brain tumors. The goal was to collect data on survival and tumor control to compare HyperArc with other treatments. The study did not test a new drug but aimed to understand how well this radiation technique works in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HyperArc stereotactic radiosurgery (a precise radiation treatment for brain tumors)
What this could lead to
If the data show HyperArc is effective, it could support its use as a standard treatment for brain metastases.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

968 people

The number who actually took part.

Started

Mar 2022

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Any patient scheduled to be treated using the HyperArc method will be invited to participate, provided they meet other eligibility criteria.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Received or scheduled to receive treatment using the HyperArc treatment method * Age of legal adult according to local law * Signed informed consent form, or, informed consent waived by the local ethics board/institutional review board Exclusion Criteria: * None, apart from not meeting Inclusion Criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain disorder central nervous system cancer central nervous system disorder metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases CNS disorder, intracranial CNS neoplasm

Contacts and locations

Locations

  • Icon Cancer Centre Canberra

    Bruce, Australian Capital Territory, 2617, Australia

  • Icon Cancer Centre Gold Coast Private

    Southport, Queensland, 4215, Australia

  • Icon Cancer Centre Greenslopes

    Greenslopes, Queensland, 4120, Australia

  • Icon Cancer Centre Maroochydore

    Maroochydore, Queensland, 4558, Australia

  • L'IRCCS Ospedale Sacro Cuore - Don Calabria

    Negrar, Valpolicella, 37024, Italy

  • University Hospital Leuven

    Leuven, 3000, Belgium

  • University of Alabama

    Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.